Fiserv earnings missed by $0.61, revenue fell short of estimates
Michael Cloonan, President and CEO of Sionna Therapeutics, Inc. (NASDAQ:SION), sold a total of 25,200 shares of common stock on October 15 and 16, 2025. The sales were executed at prices ranging from $31.1108 to $34.0, netting him approximately $788,152. The transactions occurred as the stock trades near its 52-week high of $34, following an impressive 188% gain over the past six months, according to InvestingPro data.
The transactions, were executed automatically pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
Specifically, on October 15, Cloonan sold 14,775 shares at a weighted average price of $31.1108. On October 16, he sold 10,225 shares at a weighted average price of $31.4612 and 200 shares at $34.0.
On the same dates, Cloonan also exercised options to acquire a total of 25,200 shares of Sionna Therapeutics common stock at a price of $6.11 per share, for a total value of $153,972.
Following these transactions, Cloonan directly owns 547,343 shares of Sionna Therapeutics.
In other recent news, Sionna Therapeutics has initiated a Phase 1 trial to evaluate its novel cystic fibrosis treatment combinations. The trial involves SION-451, an NBD1 stabilizer, in combination with SION-2222 and SION-109, focusing on safety and pharmacokinetics. Following the announcement of positive topline Phase I safety and pharmacokinetic data, Guggenheim reiterated a Buy rating with a $45 target, emphasizing plans to advance NBD1 stabilizers into further clinical development. Additionally, Freedom Capital Markets initiated coverage on Sionna Therapeutics with a Buy rating and a $38 price target. In contrast, RBC Capital began coverage with a Sector Perform rating and a $22 price target, noting the potential of Sionna’s CFTR modulators in the cystic fibrosis space. These developments highlight significant analyst interest and ongoing clinical progress for Sionna Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.